1. Home
  2. CIK vs MCRB Comparison

CIK vs MCRB Comparison

Compare CIK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.86

Market Cap

156.5M

Sector

Finance

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$15.92

Market Cap

140.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
MCRB
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.5M
140.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CIK
MCRB
Price
$2.86
$15.92
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$14.33
AVG Volume (30 Days)
115.4K
60.6K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
9.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.62
Revenue
N/A
$351,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$25.79
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$6.53
52 Week High
$3.19
$29.98

Technical Indicators

Market Signals
Indicator
CIK
MCRB
Relative Strength Index (RSI) 53.73 51.12
Support Level $2.79 $14.90
Resistance Level $2.87 $16.00
Average True Range (ATR) 0.02 0.77
MACD 0.00 0.20
Stochastic Oscillator 62.60 82.78

Price Performance

Historical Comparison
CIK
MCRB

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: